IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia

Brain, Behavior, and Immunity

Volumn 44, Issue , 2015, Pages 148-158

  Severance, Emily G ^a   Gressitt, Kristin L ^a   Alaedini, Armin ^b   Rohleder, Cathrin ^c   Enning, Frank ^c   Bumb, J Malte ^c   Müller, Juliane K ^c   Schwarz, Emanuel ^c   Yolken, Robert H ^a   Leweke, F Markus ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Arachnoid membrane; Autism; Bipolar disorder; Blood brain barrier; Choroid plexus; Endothelial; Epithelial; Gastrointestinal; Psychoses

Indexed keywords

ALBUMIN; CASEIN; GLUCOSE; GLUTEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; NEUROLEPTIC AGENT; ANTIBODY; GLUCOSE BLOOD LEVEL; GLUTENIN; PROTEIN INTAKE;

ALBUMIN BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; BLOOD SAMPLING; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; ADULT; BLOOD; IMMUNOLOGY; INFLAMMATION; METABOLISM; PROTEIN INTAKE;

ADULT; ANTIBODIES; BLOOD GLUCOSE; CASEINS; DIETARY PROTEINS; FEMALE; GLUCOSE; GLUTENS; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; INFLAMMATION; MALE; SCHIZOPHRENIA;

EID: 84918824053     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.09.009     Document Type: Article

References (134)

1. Aihara K., Osaka M., Yoshida M. Oral administration of the milk casein-derived tripeptide Val-Pro-Pro attenuates high-fat diet-induced adipose tissue inflammation in mice. Br. J. Nutr. 2014, 112(4):513-519.
2. Alaedini A., Okamoto H., Briani C., Wollenberg K., Shill H.A., Bushara K.O., Sander H.W., Green P.H., Hallett M., Latov N. Immune cross-reactivity in celiac disease: anti-gliadin antibodies bind to neuronal synapsin I. J. Immunol. 2007, 178(10):6590-6595.
3. Arango C., Rapado-Castro M., Reig S., Castro-Fornieles J., Gonzalez-Pinto A., Otero S., Baeza I., Moreno C., Graell M., Janssen J., Parellada M., Moreno D., Bargallo N., Desco M. Progressive brain changes in children and adolescents with first-episode psychosis. Arch. Gen. Psychiatry 2012, 69(1):16-26.
4. Barnett M.P., McNabb W.C., Roy N.C., Woodford K.B., Clarke A.J. Dietary A1 beta-casein affects gastrointestinal transit time, dipeptidyl peptidase-4 activity, and inflammatory status relative to A2 beta-casein in Wistar rats. Int. J. Food Sci. Nutr. 2014, 65(6):720-727.
5. Bauer K., Kornhuber J. Blood-cerebrospinal fluid barrier in schizophrenic patients. Eur. Arch. Psychiatry Neurol. Sci. 1987, 236(5):257-259.
6. Bechter K. Updating the mild encephalitis hypothesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:71-91.
7. Bechter K., Reiber H., Herzog S., Fuchs D., Tumani H., Maxeiner H.G. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J. Psychiatr. Res. 2010, 44(5):321-330.
8. Beumer W., Drexhage R.C., De Wit H., Versnel M.A., Drexhage H.A., Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012, 37(12):1901-1911.
9. Boutrou R., Gaudichon C., Dupont D., Jardin J., Airinei G., Marsset-Baglieri A., Benamouzig R., Tome D., Leonil J. Sequential release of milk protein-derived bioactive peptides in the jejunum in healthy humans. Am. J. Clin. Nutr. 2013, 97(6):1314-1323.
10. Briani C., Zara G., Alaedini A., Grassivaro F., Ruggero S., Toffanin E., Albergoni M.P., Luca M., Giometto B., Ermani M., De Lazzari F., D'Odorico A., Battistin L. Neurological complications of celiac disease and autoimmune mechanisms: a prospective study. J. Neuroimmunol. 2008, 195(1-2):171-175.
11. Burghardt K., Grove T., Ellingrod V. Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. J. Psychopharmacol. 2014, 28(4):349-356.
12. Burk K., Bosch S., Muller C.A., Melms A., Zuhlke C., Stern M., Besenthal I., Skalej M., Ruck P., Ferber S., Klockgether T., Dichgans J. Sporadic cerebellar ataxia associated with gluten sensitivity. Brain 2001, 124(Pt 5):1013-1019.
13. Cascella N.G., Kryszak D., Bhatti B., Gregory P., Kelly D.L., Mc Evoy J.P., Fasano A., Eaton W.W. Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. Schizophr. Bull. 2011, 37(1):94-100.
14. Chen F., Radisky E.S., Das P., Batra J., Hata T., Hori T., Baine A.M., Gardner L., Yue M.Y., Bu G., del Zoppo G., Patel T.C., Nguyen J.H. TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure. J. Cereb. Blood Flow Metab. 2013, 33(7):1041-1049.
15. Chen S.-J., Chao Y.-L., Chen C.-Y., Chang C.-M., Wu E.C.-H., Wu C.-S., Yeh H.-H., Chen C.-H., Tsai H.-J. Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. Br. J. Psychiatry 2012, 200(5):374-380.
16. Chinnery P.F., Reading P.J., Milne D., Gardner-Medwin D., Turnbull D.M. CSF antigliadin antibodies and the Ramsay Hunt syndrome. Neurology 1997, 49(4):1131-1133.
17. Clemente M.G., De Virgiliis S., Kang J.S., Macatagney R., Musu M.P., Di Pierro M.R., Drago S., Congia M., Fasano A. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 2003, 52(2):218-223.
18. Collins S.M., Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 2009, 136(6):2003-2014.
19. Corvin A., Morris D.W. Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis. Biol. Psychiatry 2014, 75(4):276-283.
20. Deli M.A. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochimica Et Biophysica Acta-Biomembranes 2009, 1788(4):892-910.
21. Demjaha A., MacCabe J.H., Murray R.M. How genes and environmental factors determine the different neurodevelopmental trajectories of schizophrenia and bipolar disorder. Schizophr. Bull. 2012, 38(2):209-214.
22. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Alaedini A., Yolken R. Markers of gluten sensitivity and celiac disease in bipolar disorder. Bipolar Disord. 2011, 13(1):52-58.
23. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Leister F., Yang S., Krivogorsky B., Alaedini A., Yolken R. Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. Biol. Psychiatry 2010, 68(1):100-104.
24. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Yang S., Yolken R. C-reactive protein is elevated in schizophrenia. Schizophr. Res. 2013, 143(1):198-202.
25. Dohan F. Genetic hypothesis of idiopathic schizophrenia: its exorphin connection. Schizophr. Bull. 1988, 14(4):489-494.
26. Dohan F.C. Wartime changes in hospital admissions for schizophrenia. A comparison of admission for schizophrenia and other psychoses in six countries during World War II. Acta Psychiatr. Scand. 1966, 42(1):1-23.
27. Dohan F.C. Wheat "consumption" and hospital admissions for schizophrenia during World War II. A preliminary report. Am. J. Clin. Nutr. 1966, 18(1):7-10.
28. Dohan F.C. Schizophrenia and neuroactive peptides from food. Lancet 1979, 1(8124):1031.
29. Dohan F.C. Hypothesis: genes and neuroactive peptides from food as cause of schizophrenia. Adv. Biochem. Psychopharmacol. 1980, 22:535-548.
30. Dohan F.C. Schizophrenia, celiac disease, gluten antibodies, and the importance of beta. Biol. Psychiatry 1981, 16(11):1115-1117.
31. Dohan F.C. Genetic hypothesis of idiopathic schizophrenia: its exorphin connection. Schizophr. Bull. 1988, 14(4):489-494.
32. Dohan F.C., Grasberger J.C. Relapsed schizophrenics: earlier discharge from the hospital after cereal-free, milk-free diet. Am. J. Psychiatry 1973, 130(6):685-688.
33. Dohan F.C., Grasberger J.C., Lowell F.M., Johnston H.T., Arbegast A.W. Relapsed schizophrenics: more rapid improvement on a milk- and cereal-free diet. Br. J. Psychiatry 1969, 115(522):595-596.
34. Drexhage R.C., Knijff E.M., Padmos R.C., Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., Drexhage H.A. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev. Neurother. 2010, 10(1):59-76.
35. Drexhage R.C., Weigelt K., van Beveren N., Cohen D., Versnel M.A., Nolen W.A., Drexhage H.A. Immune and neuroimmune alterations in mood disorders and schizophrenia. Int. Rev. Neurobiol. 2011, 101:169-201.
36. Eaton W., Mortensen P.B., Agerbo E., Byrne M., Mors O., Ewald H. Coeliac disease and schizophrenia: population based case control study with linkage of Danish national registers. Br. Med. J. 2004, 328(7437):438-439.
37. Eaton W.W., Byrne M., Ewald H., Mors O., Chen C.-Y., Agerbo E., Mortensen P.B. The association of schizophrenia and autoimmune diseases; linkage of Danish national registers. Am. J. Psychiatry 2006, 163:521-528.
38. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann. N. Y. Acad. Sci. 2012, 1258:25-33.
39. Fillman S.G., Cloonan N., Catts V.S., Miller L.C., Wong J., McCrossin T., Cairns M., Weickert C.S. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry 2013, 18(2):206-214.
40. Fillman S.G., Sinclair D., Fung S.J., Webster M.J., Shannon Weickert C. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl. Psychiatry 2014, 4:e365.
41. Gibney S.M., Drexhage H.A. Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J. Neuroimmune Pharmacol. 2013, 8(4):900-920.
42. Hadjivassiliou M., Boscolo S., Davies-Jones G.A., Grunewald R.A., Not T., Sanders D.S., Simpson J.E., Tongiorgi E., Williamson C.A., Woodroofe N.M. The humoral response in the pathogenesis of gluten ataxia. Neurology 2002, 58(8):1221-1226.
43. Hall J., Trent S., Thomas K.L., O'Donovan M.C., Owen M.J. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol. Psychiatry 2014, [Epub ahead of print].
44. Haq M.R., Kapila R., Sharma R., Saliganti V., Kapila S. Comparative evaluation of cow beta-casein variants (A1/A2) consumption on Th2-mediated inflammatory response in mouse gut. Eur. J. Nutr. 2014, 53(4):1039-1049.
45. Hayes L.N., Severance E.G., Leek J.T., Gressitt K.L., Rohleder C., Coughlin J.M., Leweke F.M., Yolken R.H., Sawa A. Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr. Bull. 2014, 40(5):963-972.
46. Holmes E., Tsang T.M., Huang J.T., Leweke F.M., Koethe D., Gerth C.W., Nolden B.M., Gross S., Schreiber D., Nicholson J.K., Bahn S. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006, 3(8):e327.
47. Horvath S., Mirnics K. Immune system disturbances in schizophrenia. Biol. Psychiatry 2014, 75(4):316-323.
48. Jackson J., Eaton W., Cascella N., Fasano A., Warfel D., Feldman S., Richardson C., Vyas G., Linthicum J., Santora D., Warren K.R., Carpenter W.T., Kelly D.L. A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr. Res. 2012, 140(1-3):262-263.
49. Jacobi C., Lange P., Reiber H. Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: discrimination between microorganism-driven and polyspecific immune response. J. Neuroimmunol. 2007, 187(1-2):139-146.
50. Jin S.Z., Wu N., Xu Q., Zhang X., Ju G.Z., Law M.H., Wei J. A study of circulating gliadin antibodies in schizophrenia among a Chinese population. Schizophr. Bull. 2010, 38(3):514-518.
51. Jong A., Huang S.H. Blood-brain barrier drug discovery for central nervous system infections. Curr. Drug Targets Infect. Disord. 2005, 5(1):65-72.
52. Kaminski S., Cieslinska A., Kostyra E. Polymorphism of bovine beta-casein and its potential effect on human health. J. Appl. Genet. 2007, 48(3):189-198.
53. Kirch D.G., Kaufmann C.A., Papadopoulos N.M., Martin B., Weinberger D.R. Abnormal cerebrospinal fluid protein indices in schizophrenia. Biol. Psychiatry. 1985, 20(10):1039-1046.
54. Kirch D.G., Alexander R.C., Suddath R.L., Papadopoulos N.M., Kaufmann C.A., Daniel D.G., Wyatt R.J. Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia. J. Neural Transm. Gen. Sect. 1992, 89(3):219-232.
55. Kuloglu M., Caykoylu A., Yilmaz E., Ekinci O. A left temporal lobe arachnoid cyst in a patient with schizophrenia-like psychosis: a case report. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(5):1353-1354.
56. Lachance L.R., McKenzie K. Biomarkers of gluten sensitivity in patients with non-affective psychosis: a meta-analysis. Schizophr. Res. 2014, 152(2-3):521-527.
57. Lambert G.P. Stress-induced gastrointestinal barrier dysfunction and its inflammatory effects. J. Anim. Sci. 2009, 87(Suppl. 14):E101-E108.
58. Lammers K.M., Lu R., Brownley J., Lu B., Gerard C., Thomas K., Rallabhandi P., Shea-Donohue T., Tamiz A., Alkan S., Netzel-Arnett S., Antalis T., Vogel S.N., Fasano A. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 2008, 135(1):194-204. e193.
59. Laterra J., Keep R., Betz L.A., Goldstein G. Blood-Cerebrospinal Fluid Barrier 1999, Lippincott-Raven, Philadelphia.
60. Lau N.M., Green P.H., Taylor A.K., Hellberg D., Ajamian M., Tan C.Z., Kosofsky B.E., Higgins J.J., Rajadhyaksha A.M., Alaedini A. Markers of celiac disease and gluten sensitivity in children with autism. PLoS ONE 2013, 8(6):e66155.
61. Leonard B.E., Schwarz M., Myint A.M. The metabolic syndrome in schizophrenia: is inflammation a contributing cause?. J. Psychopharmacol. 2012, 26(Suppl. 5):33-41.
62. Leweke F.M., Gerth C.W., Koethe D., Klosterkotter J., Ruslanova I., Krivogorsky B., Torrey E.F., Yolken R.H. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2004, 254(1):4-8.
63. Linderholm K.R., Skogh E., Olsson S.K., Dahl M.L., Holtze M., Engberg G., Samuelsson M., Erhardt S. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 2012, 38(3):426-432.
64. Lindstrom L.H., Besev G., Gunne L.M., Terenius L. CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites. Psychiatry Res. 1986, 19(2):93-100.
65. Lindstrom L.H., Nyberg F., Terenius L., Bauer K., Besev G., Gunne L.M., Lyrenas S., Willdeck-Lund G., Lindberg B. CSF and plasma beta-casomorphin-like opioid peptides in postpartum psychosis. Am. J. Psychiatry 1984, 141(9):1059-1066.
66. Maes M., Delanghe J., Bocchio Chiavetto L., Bignotti S., Tura G.B., Pioli R., Zanardini R., Altamura C.A. Haptoglobin polymorphism and schizophrenia: genetic variation on chromosome 16. Psychiatry Res. 2001, 104(1):1-9.
67. Marinescu I., Udristoiu I., Marinescu D. Choroid plexus calcification: clinical, neuroimaging and histopathological correlations in schizophrenia. Rom. J. Morphol. Embryol. 2013, 54(2):365-369.
68. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
69. Miller B.J., Mellor A., Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav. Immun. 2012, 31:82-89.
70. Modinos G., Iyegbe C., Prata D., Rivera M., Kempton M.J., Valmaggia L.R., Sham P.C., van Os J., McGuire P. Molecular genetic gene-environment studies using candidate genes in schizophrenia: a systematic review. Schizophr. Res. 2013, 150(2-3):356-365.
71. Mondelli V., Howes O. Inflammation: its role in schizophrenia and the potential anti-inflammatory effects of antipsychotics. Psychopharmacology 2014, 231(2):317-318.
72. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., Yamauchi Y., Yamada S., Kanba S. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:115-121.
73. Muller N. Immunology of schizophrenia. NeuroImmunoModulation 2014, 21(2-3):109-116.
74. Muller N., Myint A.M., Schwarz M.J. Inflammation in schizophrenia. Adv. Protein Chem. Struct. Biol. 2012, 88:49-68.
75. Mundt L., Shanahan K. Graff's Textbook of Urinalysis and Body Fluids 2011, Lippincott Williams & Wilkins, Philadelphia.
76. Narr K.L., Sharma T., Woods R.P., Thompson P.M., Sowell E.R., Rex D., Kim S., Asuncion D., Jang S., Mazziotta J., Toga A.W. Increases in regional subarachnoid CSF without apparent cortical gray matter deficits in schizophrenia: modulating effects of sex and age. Am J. Psychiatry 2003, 160(12):2169-2180.
77. Niebuhr D.W., Li Y., Cowan D.N., Weber N.S., Fisher J.A., Ford G.M., Yolken R. Association between bovine casein antibody and new onset schizophrenia among US military personnel. Schizophr. Res. 2011, 128(1-3):51-55.
78. Okusaga O., Yolken R.H., Langenberg P., Sleemi A., Kelly D.L., Vaswani D., Giegling I., Hartmann A.M., Konte B., Friedl M., Mohyuddin F., Groer M.W., Rujescu D., Postolache T.T. Elevated gliadin antibody levels in individuals with schizophrenia. World J. Biol. Psychiatry: J. World Fed. Societies Biol. Psychiatry 2013, 14(7):509-515.
79. Pedersen L., Parlar S., Kvist K., Whiteley P., Shattock P. Data mining the ScanBrit study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders: behavioural and psychometric measures of dietary response. Nutr. Neurosci. 2014, 17(5):207-213.
80. Prandi B., Faccini A., Tedeschi T., Cammerata A., Sgrulletta D., D'Egidio M.G., Galaverna G., Sforza S. Qualitative and quantitative determination of peptides related to celiac disease in mixtures derived from different methods of simulated gastrointestinal digestion of wheat products. Anal. Bioanal. Chem. 2014, 406(19):4765-4775.
81. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460(7256):748-752.
82. Reiber H. Flow rate of cerebrospinal fluid (CSF) - a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci. 1994, 122(2):189-203.
83. Reiber H., Peter J.B. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J. Neurol. Sci. 2001, 184(2):101-122.
84. Reichelt K.L. Peptides in schizophrenia. Biol. Psychiatry 1991, 29(5):515-516.
85. Reichelt K.L. Exorphins in schizophrenia and autism. J. Neurochem. 1994, 63:S86.
86. Reichelt K.L., Edminson P.D., Toft K.G. Urinary peptides in schizophrenia and depression. Stress Med. 1985, 1(3):169-181.
87. Reichelt K.L., Hole K., Hamberger A., Saelid G., Edminson P.D., Braestrup C.B., Lingjaerde O., Ledaal P., Orbeck H. Biologically active peptide-containing fractions in schizophrenia and childhood autism. Adv. Biochem. Psychopharmacol. 1981, 28:627-643.
88. Reichelt K.L., Landmark J. Specific IgA antibody increases in schizophrenia. Biol. Psychiatry 1995, 37(6):410-413.
89. Reichelt K.L., Reichelt W.H., Stensrud M. The role of peptides in schizophrenia. J. Neurochem. 1995, 65:S43.
90. Reichelt K.L., Tveiten D., Knivsberg A.M., Bronstad G. Peptides' role in autism with emphasis on exorphins. Microb. Ecol. Health Dis. 2012, 23.
91. Rimol L.M., Nesvag R., Hagler D.J., Bergmann O., Fennema-Notestine C., Hartberg C.B., Haukvik U.K., Lange E., Pung C.J., Server A., Melle I., Andreassen O.A., Agartz I., Dale A.M. Cortical volume, surface area, and thickness in schizophrenia and bipolar disorder. Biol. Psychiatry 2012, 71(6):552-560.
92. Rudin D.O. The choroid plexus and system disease in mental illness. I. A new brain attack mechanism via the second blood-brain barrier. Biol. Psychiatry 1980, 15(4):517-539.
93. Rudin D.O. The choroid plexus and system disease in mental illness. II. Systemic lupus erythematosus: a combined transport dysfunction model for schizophrenia. Biol. Psychiatry 1981, 16(4):373-397.
94. Rudin D.O. The choroid plexus and system disease in mental illness. III. The exogenous peptide hypothesis of mental illness. Biol. Psychiatry 1981, 16(5):489-512.
95. Samaroo D., Dickerson F., Kasarda D.D., Green P.H., Briani C., Yolken R.H., Alaedini A. Novel immune response to gluten in individuals with schizophrenia. Schizophr. Res. 2010, 118(1-3):248-255.
96. Sandyk R. Choroid plexus calcification as a possible marker of hallucinations in schizophrenia. Int. J. Neurosci. 1993, 71(1-4):87-92.
97. Schliep G., Felgenhauer K. Serum-CSF protein gradients, the blood-GSF barrier and the local immune response. J. Neurol. 1978, 218(2):77-96.
98. Schrodl D., Kahlenberg F., Peter-Zimmer K., Hermann W., Kuhn H.J., Mothes T. Intrathecal synthesis of autoantibodies against tissue transglutaminase. J. Autoimmun. 2004, 22(4):335-340.
99. Severance E.G., Alaedini A., Yang S., Halling M., Gressitt K.L., Stallings C.R., Origoni A.E., Vaughan C., Khushalani S., Leweke F.M., Dickerson F.B., Yolken R.H. Gastrointestinal inflammation and associated immune activation in schizophrenia. Schizophr. Res. 2012, 138(1):48-53.
100. Severance E.G., Dickerson F.B., Halling M., Krivogorsky B., Haile L., Yang S., Stallings C.R., Origoni A.E., Bossis I., Xiao J., Dupont D., Haasnoot W., Yolken R.H. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr. Res. 2010, 118(1-3):240-247.
101. Severance E.G., Dupont D., Dickerson F.B., Stallings C.R., Origoni A.E., Krivogorsky B., Yang S., Haasnoot W., Yolken R.H. Immune activation by casein dietary antigens in bipolar disorder. Bipolar Disord. 2010, 12(8):834-842.
102. Severance E.G., Gressitt K.L., Halling M., Stallings C.R., Origoni A.E., Vaughan C., Khushalani S., Alaedini A., Dupont D., Dickerson F.B., Yolken R.H. Complement C1q formation of immune complexes with milk caseins and wheat glutens in schizophrenia. Neurobiol. Dis. 2012, 48(3):447-453.
103. Severance E.G., Gressitt K.L., Stallings C.R., Origoni A.E., Khushalani S., Leweke F.M., Dickerson F.B., Yolken R.H. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr. Res. 2013.
104. Severance E.G., Yolken R.H., Eaton W.W. Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr. Res. 2014, [Epub ahead of print].
105. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., Dudbridge F., Holmans P.A., Whittemore A.S., Mowry B.J., Olincy A., Amin F., Cloninger C.R., Silverman J.M., Buccola N.G., Byerley W.F., Black D.W., Crowe R.R., Oksenberg J.R., Mirel D.B., Kendler K.S., Freedman R., Gejman P.V. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460(7256):753-757.
106. Shiga T., Wada A., Kunii Y., Itagaki S., Sakuma J., Yabe H., Saito K., Niwa S. Effective surgical intervention for schizophrenia-like symptoms and low event-related potentials caused by arachnoid cyst. Psychiatry Clin. Neurosci. 2012, 66(6):536-537.
107. Sidhom O., Laadhar L., Zitouni M., Ben A.N., Rafrafi R., Kallel-Sellami M., Lahmar H., El H.Z., Makni S. Spectrum of autoantibodies in Tunisian psychiatric inpatients. Immunol. Invest. 2012, 41(5):538-549.
108. Soderholm J.D., Perdue M.H. Stress and gastrointestinal tract. II. Stress and intestinal barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280(1):G7-G13.
109. Stangel M., Fredrikson S., Meinl E., Petzold A., Stuve O., Tumani H. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat. Rev. Neurol. 2013, 9(5):267-276.
110. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietilainen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Borglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Bottcher Y., Olesen J., Breuer R., Moller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Rethelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de Frutos R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jonsson E.G., Terenius L., Agartz I., Petursson H., Nothen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St Clair D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460(7256):744-747.
111. Steiner J., Bernstein H.G., Schiltz K., Muller U.J., Westphal S., Drexhage H.A., Bogerts B. Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 48:287-294.
112. Stojanovic A., Martorell L., Montalvo I., Ortega L., Monseny R., Vilella E., Labad J. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology 2014, 41:23-32.
113. Sun Z.Y., Wei J., Xie L., Shen Y., Liu S.Z., Ju G.Z., Shi J.P., Yu Y.Q., Zhang X., Xu Q., Hemmings G.P. The CLDN5 locus may be involved in the vulnerability to schizophrenia. Eur. Psychiatry 2004, 19(6):354-357.
114. Terryberry J.W., Thor G., Peter J.B. Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. Neurobiol. Aging 1998, 19(3):205-216.
115. Thomas K.E., Sapone A., Fasano A., Vogel S.N. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J. Immunol. 2006, 176(4):2512-2521.
116. Tibbling G., Link H., Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand. J. Clin. Lab. Invest. 1977, 37(5):385-390.
117. Torrey E.F., Bartko J.J., Yolken R.H. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr. Bull. 2012, 38(3):642-647.
118. Tsuang M. Schizophrenia: genes and environment. Biol. Psychiatry 2000, 47(3):210-220.
119. Turgut M., Erdogan S., Ergin K., Serter M. Melatonin ameliorates blood-brain barrier permeability, glutathione, and nitric oxide levels in the choroid plexus of the infantile rats with kaolin-induced hydrocephalus. Brain Res. 2007, 1175:117-125.
120. van Os J., Rutten B.P., Myin-Germeys I., Delespaul P., Viechtbauer W., van Zelst C., Bruggeman R., Reininghaus U., Morgan C., Murray R.M., Di Forti M., McGuire P., Valmaggia L.R., Kempton M.J., Gayer-Anderson C., Hubbard K., Beards S., Stilo S.A., Onyejiaka A., Bourque F., Modinos G., Tognin S., Calem M., O'Donovan M.C., Owen M.J., Holmans P., Williams N., Craddock N., Richards A., Humphreys I., Meyer-Lindenberg A., Leweke F.M., Tost H., Akdeniz C., Rohleder C., Bumb J.M., Schwarz E., Alptekin K., Ucok A., Saka M.C., Atbasoglu E.C., Guloksuz S., Gumus-Akay G., Cihan B., Karadag H., Soygur H., Cankurtaran E.S., Ulusoy S., Akdede B., Binbay T., Ayer A., Noyan H., Karadayi G., Akturan E., Ulas H., Arango C., Parellada M., Bernardo M., Sanjuan J., Bobes J., Arrojo M., Santos J.L., Cuadrado P., Rodriguez Solano J.J., Carracedo A., Garcia Bernardo E., Roldan L., Lopez G., Cabrera B., Cruz S., Diaz Mesa E.M., Pouso M., Jimenez E., Sanchez T., Rapado M., Gonzalez E., Martinez C., Sanchez E., Olmeda M.S., de Haan L., Velthorst E., van der Gaag M., Selten J.P., van Dam D., van der Ven E., van der Meer F., Messchaert E., Kraan T., Burger N., Leboyer M., Szoke A., Schurhoff F., Llorca P.M., Jamain S., Tortelli A., Frijda F., Vilain J., Galliot A.M., Baudin G., Ferchiou A., Richard J.R., Bulzacka E., Charpeaud T., Tronche A.M., De Hert M., van Winkel R., Decoster J., Derom C., Thiery E., Stefanis N.C., Sachs G., Aschauer H., Lasser I., Winklbaur B., Schlogelhofer M., Riecher-Rossler A., Borgwardt S., Walter A., Harrisberger F., Smieskova R., Rapp C., Ittig S., Soguel-dit-Piquard F., Studerus E., Klosterkotter J., Ruhrmann S., Paruch J., Julkowski D., Hilboll D., Sham P.C., Cherny S.S., Chen E.Y., Campbell D.D., Li M., Romeo-Casabona C.M., Emaldi Cirion A., Urruela Mora A., Jones P., Kirkbride J., Cannon M., Rujescu D., Tarricone I., Berardi D., Bonora E., Seri M., Marcacci T., Chiri L., Chierzi F., Storbini V., Braca M., Minenna M.G., Donegani I., Fioritti A., La Barbera D., La Cascia C.E., Mule A., Sideli L., Sartorio R., Ferraro L., Tripoli G., Seminerio F., Marinaro A.M., McGorry P., Nelson B., Amminger G.P., Pantelis C., Menezes P.R., Del-Ben C.M., Gallo Tenan S.H., Shuhama R., Ruggeri M., Tosato S., Lasalvia A., Bonetto C., Ira E., Nordentoft M., Krebs M.O., Barrantes-Vidal N., Cristobal P., Kwapil T.R., Brietzke E., Bressan R.A., Gadelha A., Maric N.P., Andric S., Mihaljevic M., Mirjanic T. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr. Bull. 2014, 40(4):729-736.
121. Veijola J., Guo J.Y., Moilanen J.S., Jaaskelainen E., Miettunen J., Kyllonen M., Haapea M., Huhtaniska S., Alaraisanen A., Maki P., Kiviniemi V., Nikkinen J., Starck T., Remes J.J., Tanskanen P., Tervonen O., Wink A.M., Kehagia A., Suckling J., Kobayashi H., Barnett J.H., Barnes A., Koponen H.J., Jones P.B., Isohanni M., Murray G.K. Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication. PLoS ONE 2014, 9(7):e101689.
122. Verma S., Kumar M., Gurjav U., Lum S., Nerurkar V.R. Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor. Virology 2010, 397(1):130-138.
123. Vojdani A., O'Bryan T., Green J.A., McCandless J., Woeller K.N., Vojdani E., Nourian A.A., Cooper E.L. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr. Neurosci. 2004, 7(3):151-161.
124. Wan C., La Y., Zhu H., Yang Y., Jiang L., Chen Y., Feng G., Li H., Sang H., Hao X., Zhang G., He L. Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene. Amino Acids 2007, 32(1):101-108.
125. Wang X.S., Fang H.L., Chen Y., Liang S.S., Zhu Z.G., Zeng Q.Y., Li J., Xu H.Q., Shao B., He J.C., Hou S.T., Zheng R.Y. Idazoxan reduces blood-brain barrier damage during experimental autoimmune encephalomyelitis in mouse. Eur. J. Pharmacol. 2014, 736:70-76.
126. Wei J., Hemmings G.P. A study of the combined effect of the CLDN5 locus and the genes for the phospholipid metabolism pathway in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2005, 73(6):441-445.
127. Whedon J.M., Glassey D. Cerebrospinal fluid stasis and its clinical significance. Altern. Ther. Health Med. 2009, 15(3):54-60.
128. Whiteley P., Haracopos D., Knivsberg A.M., Reichelt K.L., Parlar S., Jacobsen J., Seim A., Pedersen L., Schondel M., Shattock P. The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutr. Neurosci. 2010, 13(2):87-100.
129. Whiteley P., Shattock P., Knivsberg A.M., Seim A., Reichelt K.L., Todd L., Carr K., Hooper M. Gluten- and casein-free dietary intervention for autism spectrum conditions. Front. Hum. Neurosci. 2012, 6:344.
130. Yang Y., Wan C., Li H., Zhu H., La Y., Xi Z., Chen Y., Jiang L., Feng G., He L. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal. Chem. 2006, 78(11):3571-3576.
131. Ye L., Sun Z., Xie L., Liu S., Ju G., Shi J., Yu Y., Zhang X., Wei J., Xu Q., Shen Y. Further study of a genetic association between the CLDN5 locus and schizophrenia. Schizophr. Res. 2005, 75(1):139-141.
132. Yolken R.H., Torrey E.F. Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol. Psychiatry 2008, 13(5):470-479.
133. Zetterberg H., Jakobsson J., Redsater M., Andreasson U., Palsson E., Ekman C.J., Sellgren C., Johansson A.G., Blennow K., Landen M. Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res. 2014, 217(3):143-146.
134. Zhao Z., Xu J., Chen J., Kim S., Reimers M., Bacanu S.A., Yu H., Liu C., Sun J., Wang Q., Jia P., Xu F., Zhang Y., Kendler K.S., Peng Z., Chen X. Transcriptome sequencing and genome-wide association analyses reveal lysosomal function and actin cytoskeleton remodeling in schizophrenia and bipolar disorder. Mol. Psychiatry 2014, [Epub ahead of print].